Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
The evolving treatment paradigm in myelofibrosis
Ruben A. Mesa
Hematology/Oncology
Research output
:
Contribution to journal
›
Review article
›
peer-review
16
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The evolving treatment paradigm in myelofibrosis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Primary Myelofibrosis
100%
Janus Kinase 2
70%
Janus Kinase Inhibitors
55%
Fedratinib
19%
INCB018424
15%
Splenic Infarction
15%
Essential Thrombocythemia
13%
Gain of Function Mutation
13%
Therapeutics
13%
Polycythemia Vera
12%
Drug Approval
12%
Pruritus
10%
United States Food and Drug Administration
9%
Hematopoietic Stem Cells
9%
Palliative Care
9%
Fatigue
8%
Direction compound
7%
Randomized Controlled Trials
6%
Transplants
6%
Survival
5%
Mortality
5%
Infections
4%
Population
3%
Neoplasms
3%